The availability of gonadotropin therapy from FDA-approved pharmacies for men with hypogonadism and infertility.

Background: Recent changes to the Biologics Price Competition and Innovation Act of 2009 have created barriers to accessing therapy for men utilizing gonadotropins for hypogonadism and infertility.

Aim: In this study we sought to investigate ways to decrease disparities in the treatment of male hypogonadism by increasing access to gonadotropin therapy by identifying 503b outsourcing pharmacies which currently provide gonadotropin therapy.

Methods: A review of 503b compounding pharmacies was performed using the online published registry available from the US Food and Drug Administration (FDA).